Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma

NCT03992911 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03992911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03992911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma
Lead sponsor
Peking University
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 19, 2019
Completion date
June 20, 2023
Enrollment
336 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma of the bladder